Home › Research › Laboratory science
Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2
Li X, Tang X, Zeng J, Duan L, Hou Z, Li L, Guo Y, Chai C, Liu J, Wang Y, Zhu LQ, Li H, et al.. Cell, 2026-01-22
Topic: Brain proteins, microglia and lab models
Plain-language summary
Alzheimer's disease (AD) and cancer are among the most devastating diseases worldwide. Epidemiological data indicate that the incidence of AD significantly decreases in patients with a history of cancer. However, whether and how peripheral cancer may affect AD progression is yet to be studied. Here, we find that peripheral cancer inhibits amyloid pathology and rescues cognition via secretion of cystatin-c (Cyst-C), which binds amyloid oligomers and activates triggering receptor expressed on myeloid cells 2 (TREM2) in microglia, enabling microglia to degrade the pre-existing amyloid plaques in AD mice. These effects of Cyst-C are abolished by a cell-type-specific deletion (Cx3cr1 TREM2-/- ) or mutation of TREM2 (TREM2 R47H ) or Cyst-C (Cyst-C L68Q ) in microglia. Together, these findings provide significant conceptual advances into cancer neuroscience and establish therapeutic avenues that are distinct from the present amyloid-lowering strategies, aiming at degrading the existing amyloid plaques for precision-targeted AD therapy.
What this study adds
Evidence grade: Early
In mice, peripheral cancer inhibited amyloid pathology and rescued cognition via secretion of cystatin-c, which binds amyloid oligomers and activates TREM2 in microglia to degrade existing plaques, and these effects were abolished by TREM2 or cystatin-c mutations. This is animal and mechanistic work proposing a distinct therapeutic avenue, not evidence that cancer or cystatin-c treats Alzheimer's disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Li, X., Tang, X., Zeng, J., Duan, L., Hou, Z., Li, L., et al. (2026). Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. Cell. https://doi.org/10.1016/j.cell.2025.12.020
Vancouver
Li X, Tang X, Zeng J, Duan L, Hou Z, Li L, et al. Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. Cell. 2026. doi:10.1016/j.cell.2025.12.020. PMID: 41576952.
BibTeX
@article{li2026-41576952,
author = {Li, X. and Tang, X. and Zeng, J. and Duan, L. and Hou, Z. and Li, L. and Guo, Y. and Chai, C. and Liu, J. and Wang, Y. and Zhu, L. Q. and Li, H. and others},
title = {{Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2}},
journal = {Cell},
year = {2026},
doi = {10.1016/j.cell.2025.12.020},
pmid = {41576952},
url = {https://doi.org/10.1016/j.cell.2025.12.020}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Epidemiological data indicate that the incidence of AD significantly decreases in patients with a history of cancer.
- Together, these findings provide significant conceptual advances into cancer neuroscience and establish therapeutic avenues that are distinct from the present amyloid-lowering strategies, aiming at degrading the existing amyloid plaques for precision-targeted AD therapy.
Why it matters
In mice, peripheral cancer inhibited amyloid pathology and rescued cognition via secretion of cystatin-c, which binds amyloid oligomers and activates TREM2 in microglia to degrade existing plaques, and these effects were abolished by TREM2 or cystatin-c mutations. This is animal and mechanistic work proposing a distinct therapeutic avenue, not evidence that cancer or cystatin-c treats Alzheimer's disease in people.
Study details
- Evidence strengthEarly
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 47 of the 98 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cell) |
| Journal's citation record | 4 / 4 | Cell: journal h-index 1,220 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 82.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Youming Lu: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Huazhong University of Science and Technology: institution h-index 934 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41576952) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 47 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 47 of the 98 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Related studies in Laboratory science from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.